Precision Oncology: 2024 in Review

Matteo Repetto(Memorial Sloan Kettering Cancer Center), Nicole Fernandez(Memorial Sloan Kettering Cancer Center), Alexander Drilon(Memorial Sloan Kettering Cancer Center), Debyani Chakravarty(Memorial Sloan Kettering Cancer Center)
Cancer Discovery
December 2, 2024
10.1158/2159-8290.cd-24-1476
Cited by 15

Abstract

This article discusses the specific advances made in precision oncology in 2024. We comment on the evolving nature of predictive molecular events used to select patients who will most benefit clinically from treatment. We also discuss advances in the development of strategic treatment regimens for combination therapies, rational drug design of small-molecule inhibitors, and structurally informed drug repurposing.

Related Papers

<i>MTAP</i> deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
Gregory V. Kryukov, Frederick H. Wilson, Jason R. Ruth et al.|Science|2016|642
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
Sarah P. Suehnholz, Moriah H. Nissan, Hongxin Zhang et al.|Cancer Discovery|2023|383
Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions
Caicun Zhou, Kejing Tang, Byoung Chul Cho et al.|New England Journal of Medicine|2023|339
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Matthew Holderfield, Bianca J. Lee, Jingjing Jiang et al.|Nature|2024|308
Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Neil Vasan, Pedram Razavi, Jared L. Johnson et al.|Science|2019|294